Hangzhou Jiuyuan Gene Engineering Co., Ltd., based in China, has announced that its market approval filing for a biosimilar version of semaglutide, originally developed by Denmark’s Novo Nordisk, has been accepted for review in China. This biosimilar is aimed at controlling blood glucose levels in patients with type 2 diabetes (T2D) and is positioned as the first semaglutide biosimilar to reach the market approval filing stage in China.
Jiuyuan Gene previously made headlines as the first domestic company to receive clinical trial approval for its biosimilar version of Novo Nordisk’s Victoza (liraglutide) in 2016, which subsequently became the first generic version to gain market approval in 2023. Additionally, Jiuyuan Gene was the first domestic firm to be authorized to conduct studies on a semaglutide biosimilar, highlighting its pioneering role in the Chinese biosimilar market.- Flcube.com
